{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002145088,0.0002986382,0.002299356,0.0003396299,0.0001196056,0.00001883251,0.0002688412,0.0003430252,0.0006943983],"category_scores_gemma":[0.001115085,0.0001912593,0.0003256088,0.0002493767,0.0006548744,0.0002781674,0.00007010836,0.002338805,0.000001079243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004381832,"about_ca_system_score_gemma":0.002986384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001240809,"about_ca_topic_score_gemma":0.0001968207,"domain_scores_codex":[0.9948403,0.0007970532,0.002415567,0.0003954509,0.001044066,0.0005075799],"domain_scores_gemma":[0.9949994,0.001358606,0.001886903,0.0002381147,0.000937761,0.0005792216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.3893892,0.03580938,0.2564836,0.0001730424,0.001068554,0.0002874907,0.001490457,6.277369e-7,0.003964001,0.00001282697,0.0001280745,0.3111928],"study_design_scores_gemma":[0.2802149,0.09672716,0.620207,0.0002387832,0.0001634416,0.0001141026,0.0001114601,0.000008657496,0.001800812,0.00001776745,0.0002456621,0.0001502793],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943802,0.0001513959,0.000005743733,0.003007875,0.0006540613,0.001618854,0.0001037428,0.000009105857,0.00006907446],"genre_scores_gemma":[0.9975204,0.0003848576,0.001035235,0.0001748878,0.0007341576,0.00005255288,0.000007252855,0.00005035172,0.00004022827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3637234,"threshold_uncertainty_score":0.9999629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1176703880999536,"score_gpt":0.4940915774878471,"score_spread":0.3764211893878935,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}